New biotech venture going viral in battle against cancer

The scientific team behind Viralytics, a Hunter-based biotech firm bought in 2018 by Merck for a record $502 million, is reuniting for a new private venture aiming to develop cutting-edge cancer therapies.

Read the full story here

Continue reading

Join Our Mailing List

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Our mission is to improve outcomes for patients with cancers in which immunotherapy treatments have limited effect